Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field study

Benjamin J Visser1,2,3, Janneke Meerveld-Gerrits1,4, Daniëlle Kroon1,2, Judith Mougoula2, Rieke Vingerling1,2, Emmanuel Bache2, Jimmy Boersma1, Michèle van Vugt1, Selidji T Agnandji2,3, Harparkash Kaur5 and Martin P Grobusch1,2,3*

Abstract

Background: Recent studies alluded to the alarming scale of poor anti-malarial drug quality in malaria-endemic countries, but also illustrated the major geographical gaps in data on anti-malarial drug quality from endemic countries. Data are particularly scarce from Central Africa, although it carries the highest burden of malaria. The aim of this medicine quality field survey was to determine the prevalence of poor-quality anti-malarial drugs in Gabon.

Methods: A field survey of the quality of anti-malarial drugs in Gabonese pharmacies was conducted using the Global Pharma Health Fund Minilab® tests, following the Medicine Quality Assessment Reporting Guidelines. Anti-malarial drugs were purchased randomly from selected pharmacies in Gabon. Semi-quantitative thin-layer chromatography (TLC) and disintegration testing were carried out to measure the concentration of active pharmaceutical ingredients (APIs). The samples failing the TLC test were analysed by high-performance liquid chromatography. Following the collection of anti-malarial drugs, a street survey was conducted to understand where people purchase their anti-malarial drugs.

Results: A total of 432 samples were purchased from 41 pharmacies in 11 cities/towns in Gabon. The prevalence of poor-quality anti-malarial drugs was 0.5% (95% CI 0.08–1.84%). Two out of 432 samples failed the MiniLab® semi-quantitative TLC test, of which a suspected artemether-lumefantrine (AL) sample was classified as falsified and one sulfadoxine-pyrimethamine (SP) sample as substandard. High performance liquid chromatography with ultraviolet photo diode array detection analysis confirmed the absence of APIs in the AL sample, and showed that the SP sample did contain the stated APIs but the amount was half the stated dose. Of the people interviewed, 92% (187/203) purchased their anti-malarial drugs at a pharmacy.

Conclusion: Using the GPHF Minilab®, the prevalence of poor-quality anti-malarial drugs is far lower than anticipated. The findings emphasize the need for randomized and robust sampling methods in order to collect representative data on anti-malarial drug quality.

Trial registration: NTR4341 (Dutch Trial Registry)
Background

*Plasmodium falciparum* malaria is estimated to cause 528,000 deaths and 163 million clinical episodes in Africa [1]. Early diagnosis and treatment with appropriate anti-malarial drugs can prevent severe illness and lethal outcome [2–4]. Therefore, it is crucial that the administered anti-malarial drugs are of acceptable quality [5]. In Gabon, the majority of anti-malarial drugs are purchased directly by the patient or caretaker from the pharmacy (licensed and unlicensed) for self- or home treatment. There is no anti-fake medicine programme, nor an effective drug regulatory system in Gabon (Additional file 1). Gabon does not receive international donor support for anti-malarial medicines. The national malaria control programme of Gabon does not provide anti-malarials for free. Whether quality assured or falsified, anti-malarial drugs have not been reported from the Gabonese markets as from the neighbouring countries. The spread of poor-quality [6, 7] (e.g., counterfeit or falsified) anti-malarial drugs may pose an obstacle to effective malaria control. Poor-quality anti-malarial drugs have serious consequences for public health [5]. Drugs with too little, or devoid of active pharmaceutical ingredients (APIs) may cause increased morbidity and mortality [8]. Also, low concentrations of APIs in poor-quality drugs will result in sub-therapeutic concentrations of the drug in vivo, which may contribute to the selection of resistant parasites [9]. Furthermore, the use of poor-quality anti-malarial drugs leads to financial loss for patients and their families, healthcare systems and pharmaceutical companies producing the genuine product [10]. The general public can lose confidence in a pharmaceutical brand, drugs, pharmacies, and healthcare providers [11].

A systematic review in 2014 illustrated the alarming scale of poor anti-malarial drug quality in malaria-endemic countries, but also showed major geographical gaps, with no published information on the quality of anti-malarial drugs from 60.6% (63/104) of the malaria-endemic countries [12]. Using the Worldwide Antimalarial Resistance Network (WWARN) [13] database, it was demonstrated that out of 9,348 anti-malarial drugs collected (compiled from 130 publications in total),
30.1% (2,813) failed chemical/packaging quality tests with 39.3% classified as falsified; 2.3% as sub-standard and 58.3% as poor-quality, without evidence available to categorize them as either sub-standard or falsified [12]. There are few reports originating from Central Africa. Also for Gabon, systematic data on the geography and epidemiology of poor-quality anti-malarial drugs is scarce. Gabon is a high-endemicity country for malaria [14–16]. A study in 2011, assessing the quality of chloroquine tablets in 12 African countries collected two chloroquine samples from the capital of Gabon (Libreville), which were both of good quality [17]. The World Health Organization (WHO) investigation in 2003 collected 25 chloroquine samples (29% poor-quality) and ten sulfadoxine-pyrimethamine samples (100% good quality) from pharmacies in Libreville. A limited number of reports are available from neighbouring countries Cameroon [5, 17–22], Equatorial Guinea [23] and the Republic of Congo [5].

The aim of this study was to determine the prevalence of poor-quality anti-malarial drugs in Gabon, which lacks an effective national product quality monitoring programme (see Additional file 1). Information about the quality of anti-malarial drugs is important for improving malaria treatment and to successfully run malaria control programmes [24, 25].

Methods

Registration and reporting

This medicine quality field survey was registered in advance (30 Dec 2013) in The Netherlands Trial Registry (NTR): NTR4341 [26]. This report follows, where appropriate, the Medicine Quality Assessment Reporting Guidelines (MEDQUARG) [27, 28]. Also, the costs of this study are reported [29] (Additional file 2).

Scientific research and ethical committee statement

Scientific clearance was obtained from the Scientific Review Committee (SRC) of the Centre de Recherches de Médecines de Lambaréné (CERMEL), Albert Schweitzer Hospital (SRC number: 2013.11; Additional file 3). The Ethical Committee of CERMEL decided that ethical approval of this study was not required as this study is a quality assurance in healthcare study, no humans having been subjected to it [30].

Study area

Gabon (an upper-middle income country, GDP $19.34 billion, 2013) straddles the Equator. About 80% of its 267,667 km² area is covered by dense tropical rainforest. The population of Gabon is estimated to be around 1.6 million inhabitants (6.3 inhabitants/km²), 86.2% of whom live in urban areas. CERMEL is based in Lambaréné, the capital of the Moyen-Ogooué Province, a semi-urban town of about 30,000 inhabitants surrounded by villages. Gabon is administratively divided into nine provinces, with villages mainly located along roads and rivers. Gabon is a highly malaria-endemic country. The official first-line treatment for uncomplicated falciparum malaria is artesunate + amodiaquine (AS + AQ) [31] or artemether-lumefantrine (AL) and severe falciparum malaria is treated with intravenous quinine. Intramuscular use of artemether or intravenous artesunate is not common in Gabon.

Primary and secondary outcomes

The primary outcome was the proportion (percentage) of poor-quality anti-malarial drugs in pharmacies in Gabon. Secondary outcomes were the proportion of outlets selling poor-quality anti-malarial drugs and availability of anti-malarial drugs that are no longer recommended as first- or second-line treatment in Gabon or by WHO. The following secondary outcome was added during the study to assess the external validity of the field survey: to determine where people purchased their anti-malarial drugs.

Definitions

The overarching term ‘poor-quality drugs’ is used to describe the different categories: falsified medicines are fake medicines that are designed to mimic real medicines; counterfeit medicines are medicines that do not comply with intellectual-property rights or that infringe trademark law.

Timing and location of the survey

The field survey was conducted in January 2014 in Gabon. The six (out of nine) most populated provinces (ISO 3166-2:GA) were selected: Estuaire; Haut-Ogooué, Moyen-Ogooué, Ngounié, Ogooué-Maritime, and Woleu-Ntem. Selected locations were: Libreville (capital), Franceville, Lambaréné, Mouila, Port-Gentil, Oyem, Bitam, Owendo, Fougamou, Makouke, Bifoun, Gamba, and Lopé (Figure 1).

Sampling design and sample size

There are approximately 75 open and fully functioning pharmacies in Gabon (2013) [32]. Pharmacies were randomly selected. The randomization procedure was performed by BJV using statistical software (nQuery Advisor® Version 7.0. Statistical Solutions, Cork, Ireland) on the day before the actual sampling. A full list provided by the Health Authorities of Gabon and a list from the National Health Assurance Company (La Caisse Nationale d’Assurance Maladie et de Garantie Sociale du Gabon [33], CNAGMS) with registered/licensed pharmacies and dispensaries was prepared.
(before sampling) to allow for proper randomization procedures. This list was accomplished with (unlisted) pharmacies by local nurses and fieldworkers. In total, six pharmacies were found which were missing on the CNAGMS list of pharmacies in Gabon. In Lambaréné (Moyen-Ogooué Province), where the CERMEL is based, all known pharmacies (n = 7) were sampled during the first week of the sampling period and thus not randomly selected. In all other areas, approximately 50% of the pharmacies were randomly selected in all neighbourhoods. Hospitals (except for the Albert Schweitzer Hospital), markets, grocery shops, and street peddlers were not visited because regulations for drug selling are in place; previsits by local nurses yielded little evidence (if any) of anti-malarial drugs sold there. The appropriate sample size and strategy is challenging, since data of the prevalence of poor-quality anti-malarial drugs are very scarce for Gabon. Thus, the most conservative sample size is given by using an unknown prevalence \[ h ] \text{[hypothesized 50\% frequency of outcome factor in the population (p)]}. To determine the actual prevalence of poor-quality drugs available in Gabon with a precision of 5\% with 95\% confidence intervals \( z = 1.96 \), a random sample of 384 was needed. The following equation was used: sample size \[ n = [\text{DEFF} \cdot Np(1 - p)]/[(d^2/Z^2_{1-\alpha/2}) \cdot (N - 1) + p \cdot (1 - p)]. \] The sample size was calculated with OpenEpi (Open Source Epidemiologic Statistics for Public Health) version 3.03 [34].

**Sampling procedure**

A Gabonese ‘mystery shopper’ (JM, nurse, of Gabonese nationality) conducted the actual sampling process in Moyen-Ogooué (177/432 samples) and was trained utilizing standard sampling guidelines. She dressed according to regular Gabonese standards and gave no indication that she was not a regular shopper. A standard scenario was used: she asked which anti-malarial drugs were for sale. Subsequently, she purchased one full child/adult treatment in their original packaging of each of the available anti-malarials and of each available brand, but not of each available batch. Samples included drugs sold in the manufacturer’s original packaging as well as those distributed loose, often in plastic bags. Surprisingly, sellers never asked questions.
Although the US Pharmacopeia (USP) recommends 30 dosage units [35] for a single tablet of the same lot number from each location, this was not deemed practically feasible in the Gabonese setting, and also too expensive. For logistical reasons the other 255/432 (60%) samples were collected by the investigators. Anti-malarial drugs purchased included: AL, AS + AQ, AS + sulfadoxine, AS-mefloquine, dihydroartemisinin-piperaquine, dihydroartemisinin-piperaquine-trimethoprim, artemisinin-piperaquine, artemisinin-naphtoquine, quinine, sulfadoxine-pyrimethamine (SP), mefloquine, proguanil, atovaquone-proguanil, proguanil-chloroquine, pyrimethamine and chloroquine. Other anti-malarial drugs were not purchased. Only solid dosage forms were collected (no liquid formulations). To avoid potential bias in subsequent sampling rounds, the exact reason for sampling medicines was not shared with the seller. Results were not reported back to the seller. For every sample collected, the collector completed and signed the sample collection form (including GPS locations) (Additional file 4) as soon as possible after leaving the point of sale and before performing the next purchase. Once purchased, all drugs were stored until testing at room temperature (in an air-conditioned room) with no sunlight. Humidity could not be controlled. Tests were completed at the laboratory of the Academic Medical Centre (AMC, The Netherlands) within 3 months of sample collection.

**Questionnaire**

To determine where people purchased their anti-malarial drugs, a questionnaire was presented to food market dwellers in Lambaréné as well as at PK (‘point kilomètre’) 8 Le Marché Bananes (a transportation hub) and Marché du Mont-Bouët in Libreville. The survey was conducted according to an earlier published method [38]. For fixed-dose combinations (e.g., AL) and SP, ‘pass’ was awarded only if both active ingredients met this standard. TLC is an accepted method to assess the quality of drugs [37, 38]. The MiniLab protocols have been reviewed by the Promoting the Quality of Medicines (PQM) programme operated by the USP Convention. Each sample/test was run twice on separate days (once by BJV, once by JMG), with the assumption that the result most consistent with the reference was recorded. Thus, every API in every sample was tested twice. Standard operating procedures (SOP) provided with the Minilab were used [36]. Quality control of the GPHF MiniLab® was performed daily before the drug testing and consisted of performing TLC on Minilab-reference samples for the anti-malarial drug analysed. In addition, Minilab reagents were quality control tested, using reference samples when a new lot was introduced. Samples were also tested to see if they disintegrated in purified water, following the guidelines of the European Pharmacopeia (EP) [39]. For this, apparatus A as described in the EP 2.9.1. was used at the laboratory of the Pharmaceutical Technology and Biopharmacy Department of Utrecht University (Utrecht, The Netherlands). Since the disintegration test requires six tablets per test, not all samples could be analysed. To include as many samples as possible, it was decided to test the samples per batch number instead of per sample. All samples with the same batch (or LOT) number, were expected to be homogeneous [40]. Samples failing TLC were analysed using the high-performance liquid chromatography with ultraviolet photo-diode array detection (HPLC–UV-PDA [41] February 2015 in a reference laboratory at the London School of Hygiene and Tropical Medicine) to quantify the amount of APIs present in each sample. This was compared with the stated dose on the packaging and the spectra achieved using a quality assured sample. For artemisinin derivatives, the artemisinin derivative screening test (ADST) was conducted according to an earlier published method [38]. Not all samples were analysed by HPLC–UV-PDA (the gold standard) due to lack of funding.

The packaging analysis was developed in line with previously published research [5, 27]. For the packaging analysis, genuine samples were requested by email from the manufacturers using a standard letter; with two reminders sent 2 and 4 weeks after the first email. Unfortunately no genuine anti-malarial samples were received.
Statistical analysis
Descriptive statistics were performed using SPSS 20.0 statistical package (SPSS Inc., Chicago, MI, USA). The confidence interval of the prevalence estimate was calculated using the Wilson procedure with a correction for continuity. Fisher’s exact test was used to calculate the difference between the number of poor-quality drugs of the Gabonese mystery shopper versus two European researchers. Inter-observer reliability (for chemical analysis) was calculated using the Kappa (κ) statistic [42].

Sharing data with Medicine Regulatory Agency
The results of this field survey were shared with the Medicine Regulatory Agency (MRA) in Gabon, the Director of Health of the Province Moyen-Ogooué and Rapid Alert of the WHO.

Results
The samples purchased in this field survey were readily available over the counter without prescription in all pharmacies. In total, 432 full anti-malarial treatments were collected from 41 pharmacies and one hospital (Albert Schweitzer Hospital, Lambaréné) in 11 cities/towns in Gabon (Table 1; Figure 1). From the collected data, 55% (41/75) of pharmacies in Gabon were surveyed. The ‘class’ of pharmacy and licensing status (e.g., public, private for profit, private not for profit, informal) was not determined and the drug sellers were not interviewed.

Of the 432 collected samples, 338 (78%) were artemisinin-based combination therapy (ACT). AS + AQ, the national recommended first-line treatment for falciparum malaria, comprised 10% of the total samples (n = 42). The second-line anti-malarial drug combination is AL and the third-line drug combination is dihydroartemisinin-piperaquine. An ACT was available in every surveyed pharmacy, but AS-AQ was only available in 27 pharmacies (65%). On average, ten full anti-malarial treatments were collected per pharmacy (min–max: 3–20). Two samples were expired at the day of purchase, both collected in a pharmacy in Lambaréné. They were not classified as sub-standard. No chloroquine or artesunate monotherapy was for sale in all the surveyed pharmacies.

Chemical analysis: semi-quantitative thin-layer chromatography (TLC)
All samples were analysed in duplicate on separate days (Table 2). Inter-observer agreement was good for TLC testing (κ = 1, 100% agreement). Thirteen samples were expired before analysis, but analysed anyway since they were sold. All samples met the requirements for uniformity of UV spots (254 nm light), which meant that all samples were analysed correctly. Only two of the 432 (0.5%)

| Table 1 Anti-malarial drugs collected | Collected and analyzed with TLC (%) | Samples included in disintegration test (% of TLC tested) | Expired before analysis | TLC failures | Disintegration test failures | Average costs (USD) |
|--------------------------------------|-------------------------------------|--------------------------------------------------------|------------------------|-------------|----------------------------|---------------------|
| ACT                                  | 177 (41%)                           | 102 (58%)                                              | 3                      | 1           | 0                          | 7.6                 |
| Artemether-lumefantrine              | 42 (10%)                            | 22 (52%)                                               | 6                      | 0           | 0                          | 7.2                 |
| Artesunate-amodiaquine               | 36 (8%)                             | 26 (72%)                                               | 1                      | 0           | 0                          | 8.5                 |
| Dihydroartemisin-piperaquine         | 38 (9%)                             | 33 (86%)                                               | 1                      | 0           | 0                          | 9.9                 |
| Artesunate-mefloquine                | 22 (5%)                             | 5 (23%)                                                | 1                      | 0           | 0                          | 9.7                 |
| Dihydroartemisin-piperaquine-trimethoprim | 13 (3%)                        | 12 (92%)                                               | 0                      | 0           | 0                          | 9.3                 |
| Dihydroartemisin-SP                  | 7 (2%)                              | 0 (0%)                                                 | 0                      | 0           | 0                          | 4.5                 |
| Artemisinin-piperaquine              | 2 (<1%)                             | 0 (0%)                                                 | 0                      | 0           | 0                          | 10.1                |
| Artemisinin-naphtoquine              | 1 (<1%)                             | 0 (0%)                                                 | 0                      | 0           | 0                          | NR                  |
| Other                                 |                                     |                                                        |                        |             |                            |                     |
| Quinine                              | 43 (10%)                            | 34 (79%)                                               | 0                      | 1           | 0                          | 9.6                 |
| Sulphadoxine-pyrimethamine           | 40 (9%)                             | 26 (65%)                                               | 0                      | 0           | 1                          | 2.2                 |
| Mefloquine                           | 4 (<1%)                             | 2 (50%)                                                | 0                      | 0           | 0                          | 33.3                |
| Atovaquone-proguanil                 | 2 (<1%)                             | 0 (0%)                                                 | 0                      | 0           | 0                          | 24.2                |
| Proguanil                            | 2 (<1%)                             | 0 (0%)                                                 | 0                      | 0           | 0                          | 16.5                |
| Proguanil-chloroquine                | 2 (<1%)                             | 0 (0%)                                                 | 1                      | 0           | 0                          | 25.2                |
| Pyrimethamine                        | 1 (<1%)                             | 0 (0%)                                                 | 0                      | 0           | 0                          | NR                  |
| Total                                | 432 (100%)                          | 266 (62%)                                              | 13 (3%)                | 2           | 1                          | 8.1                 |

TLC semi-quantitative thin-layer chromatography.
Table 2 Summary of formulations tested with the brand name, manufacturer, dose, dosage form, ACT Watch Antimalarial database status and WHO prequalification list

| Brand name/manufacturer | Generic name and dose | ACT Watch Antimalarial Database Antimalarial category | Regulatory status in Gabon |
|-------------------------|-----------------------|-------------------------------------------------------|-----------------------------|
| Alaxin-SP®, Bliss GVS Pharma LTD, India | Dihydroartemisinin + SP tablet 60/500/25 mg | Non-quality assured ACT | Unknown |
| Arco®, Kunming Pharmaceutical Corp, China | Artemisinin-naphthoquine tablet 125/50 mg | Non-quality assured ACT | Unknown |
| Arsequinoforome®, Sanofi Aventis, Cote d’Ivoire | Quinine tablet 250 mg | Non-artemisinin therapy | Unknown |
| Artecom®, Tonghe Pharmaceutical Co. Ltd, China | Dihydroartemisinin-piperaquine-trimethoprim tablet 32/320/90 mg and 16/160/45 mg | Non-quality assured ACT | Unknown |
| Artedar®, Plethico Pharma Ltd, India | Artesunate-SP tablet 100/500/25 mg | Non-quality assured ACT | Unknown |
| Artediam®, Adams Pharmaceutical (Anhui) Co., Ltd. | Artesunate-amodiaquine tablet 100/300 mg | Not listed, category unknown. | Approval at national level |
| Artefan®, Ajanta Pharma Ltd, India | Artemether-lumefantrine tablet 20/120 mg | QAACT (Quality-assured ACT) | A (MA092, 2012-Dec-19)—WHO prequalification Approval at national level |
| Artequick®, Artepharm Co.Ltd, China | Artemisinin-piperaquine tablet 62.5/375 mg | Non-quality assured ACT | Unknown |
| Artequin®, Mepha Ltd, Switzerland | Artesunate-mefloquine tablet 200/250 mg | QAACT (Quality-assured ACT) | B |
| Artim®, Twight Litaka Pharma Limited Ltd, India | Artesunate-mefloquine tablet 100/125 mg | Non-quality assured ACT | Unknown |
| Artiz (Forte), Alice Pharma Pvt Ltd, India | Artemether-lumefantrine tablet 40/240 mg and 20/120 mg | Not listed, category unknown | Unknown |
| ASAQ Denk®, Denk Pharma, Germany | Artesunate-amodiaquine tablet 100/270 mg | Non-quality assured ACT | Unknown |
| Asunate Denk®, Denk Pharma, Germany | Artesunate-SP tablet 200/500/25 mg and 100/250/12,5 mg | Not listed, manufacturer unknown | Approval at national level |
| Chinther®, Alkema Laboratories LTD, India | Artemether-lumefantrine tablet 40/240 mg | Not listed, brand and manufacturer unknown | Unknown |
| Co-Arinate®, Famar Italia Spa, Italy | Artesunate-SP tablet 200/500/25 mg and 100/250/12,5 mg | Not listed, manufacturer unknown | Unknown |
| Coarsucam®, Sanofi Aventis, Morocco | Artesunate-amodiaquine tablet 50/135 mg | QAACT (Quality-assured ACT) | MA057 (2008-Oct-14)/MA058 2008-Oct-14/MA056 (2008-Oct-14), WHO prequalification |
| Co-Artex®, GA Pharma, Greece | Dihydroartemisinin-piperaquine tablet 40/320 mg | Non-quality assured ACT | Unknown |
| Cofantrine®, Bliss GVS Pharma Ltd, India | Artemether-lumefantrine tablet 20/120 mg and 80/470 mg | Not listed, unknown manufacturer | Approval at national level |
| Cofantrine®, EGR Pharma, Luxembourg | Artesunate-amodiaquine tablet 100/270 mg | Non-quality assured ACT | Unknown |
| Colart®, Glaxosmithkline Group Of Companies, India | Artemether-lumefantrine tablet 20/120 mg | Non-quality assured ACT | Unknown |
| Combinal®, Ajanta Pharma Ltd, India/ Mauritus | SP tablet 500/25 mg | Non-artemisinin therapy | Unknown |
| Darte-Q®, Gosun Pharma Corp, China | Dihydroartemisinin-piperaquine tablet 40/320 mg | Non-quality assured ACT | Unknown |
| Duo-Cotecxin®, Beijing Holley-Cotec Pharmaceutical Ltd, China | Dihydroartemisinin-piperaquine tablet 40/320 mg | Non-quality assured ACT | Unknown |
samples analysed failed the TLC 0.5% (95% CI 0.08–1.84%). The first failed sample was AL 20/120 mg (Coartem®) (Figure 2), with batch number F2261, manufacture date 01.2012 and expiry date 01.2016. This sample was collected in a pharmacy in Bitam, a town 30 km south of the border with Cameroon. The genuine product is manufactured by Novartis and is a WHO pre-qualified medicine (Table 2). This sample did not contain any APIs. Storage conditions in Gabon or during transport are not expected to have been of any influence, given AL's excellent stability profile in humid and hot conditions [43]. This batch number is also known to be falsified: in November 2013, a drug alert of the WHO was issued describing falsified batches of Coartem® circulating in Cameroon [44]. The sample bears the falsified green leaf logo of the Affordable Medicines Facility—Malaria (AMFm) programme. There were actually made of calcium phosphates, fatty acids and yellow pigment, according to a copy of a Novartis analysis of the tablets reviewed by The Wall Street Journal [45, 46]. Another important clue for falsification is the interval between manufacturing and expiry date, which was 4 years in this sample, but should be 23 months. The other sample that failed TLC testing was SP 500/25 mg, Maloxine® (Batch No. EM-304; Mfg. date: 04/2011; Exp. Date 08/2014; Code: MH/DRUGS/670 (Figure 3). No packaging analysis of the second failed

Table 2 continued

| Brand name/manufacturer | Generic name and dose | ACT Watch Antimalarial Database Antimalarial category | Regulatory status in Gabon |
|-------------------------|-----------------------|-------------------------------------------------------|---------------------------|
| Falquin®, Plethico pharmaceutical Ltd, India | Quinine tablet 300 mg | Not listed, manufacturer unknown | Unknown |
| Fansidar®, F. Hoffmann-La Roche Ltd, Switzerland | SP tablet 500/25 mg | Non-artemisinin therapy | Unknown |
| Lariam®, F. Hoffmann-La Roche Ltd, Switzerland | Mefloquine tablet 250 mg | Non-artemisinin therapy, country of manufacture not listed | Unknown |
| Lanetem®, IPCA Laboratories Ltd, India | Artemether-lumefantrine 20/120 mg and Artemether-lumefantrine 80/480 mg | Non-quality assured ACT Dosage not listed | A (MA062, 2009-Dec-15) WHO prequalification |
| Lufanter®, Bliss Gvs Pharma Ltd, India | Artemether-lumefantrine 20/120 mg and 80/480 mg | Non-quality assured ACT | Approval at national level |
| Lumart®, Cipla Ltd, India | Artemether-lumefantrine tablet 20/120 mg and Artemether-lumefantrine tablet 40/240 mg | QAACT (Quality-assured ACT) Dosage not listed | A (MA064, 2009-May-22) WHO prequalification |
| Malacur®, Elder Pharmaceuticals LTD, India | Dihydroartemisinin-piperazine tablet 40/320 mg | Non-quality assured ACT Brand known, manufacturer not listed | Approval at national level |
| Malani®, Glaxosmithkline Group Of Companies, Canada | Atovaquone-proguanil tablet 250/100 mg | Non-artemisinin therapy | Unknown |
| Maloxine®, Gracure Pharmaceuticals Ltd, India | SP tablet 500/25 mg | Non-artemisinin therapy Brand known, manufacturer not listed | Unknown |
| Mephaquin®, Mepha Ltd, Switzerland | Mefloquine tablet 250 mg | Non-artemisinin therapy | Unknown |
| P-Alaxon®, Bliss Gvs Pharma Ltd, India | Dihydroartemisinin-piperazine tablet 40/320 mg | Non-quality assured ACT | Approval at national level |
| Paludrine®, Astra Zeneca UK Limited, United Kingdom | Proguanil tablet 100 mg | Prophylaxis | B |
| Pharmasucam®, Madras Pharmaceuticals, India | Artesunate-amodiaquine 100/270 mg | Not listed, brand name and manufacturer unknown | Unknown |
| Quinimax®, Sanofi Aventis, Spain | Quinine 500 mg and 125 mg | Non-artemisinin therapy | Unknown |
| R-Lume®, Impact Healthcare Pvt Ltd, India | Artemether-lumefantrine tablet 80/480 mg | Not listed, brand name and manufacturer unknown | Unknown |
| Savarine®, Astazeneca Ltd, France | Proguanil-chloroquine tablet 200/100 mg | Non-artemisinin therapy | Unknown |
| Sharlum®, Sharon Big-medicine Ltd, India | Artemether-lumefantrine tablet 80/480 mg and 40/240 mg | Not listed, brand name and manufacturer unknown | Unknown |
| Surquina®, Laboratoire Innotech International, France | Quinine tablet 250 mg | Non-artemisinin therapy | Unknown |

A classified product—listed on WHO prequalification list, B classified product—Stringent National Drug Regulatory Authority Registration letter/Marketing Authorization. ACT Watch Antimalarial Database: [http://www.actwatch.info/databases/antimalarial_survey_data/az] WHO prequalification. [http://apps.who.int/prequal/query/ProductRegistry.aspx].
sample was conducted, as results of previous attempts to collect genuine samples and batch information from the stated manufacturer for comparative assessment were unsuccessful.

There was no statistic significant difference (Fisher’s exact test, P = 0.311) in the number of poor-quality drugs collected by the Gabonese mystery shopper versus two European researchers (BJV and DK).

High-performance liquid chromatography (HPLC) and artemisinin derivative screening test (ADST)

Both the ARST test (no colour produced) and HPLC (no peak on the spectra) analysis indicated the absence of API in the sample of Coartem batch no. F2261. In the suspect Maloxine sample batch no. EM-304 the stated APIs were detected, but the amount was approximately half the dose.

Disintegration test

In total, 266 samples (62%) were tested for disintegration. Not all (n = 432) samples were tested because one disintegration test requires six tablets per test. Samples were tested per batch. One sample (0.4%) failed the disintegration test (Coartem sample that also failed the TLC and HPLC). The disintegration time of the Maloxine sample that failed the TLC test could not be tested, because the SP sample contains only three tablets in total. For detailed results of disintegration test per batch number see Additional file 5.

Manufacturers and registration status

Forty-three different brands were collected. Most packagings/accompanying leaflets of the drugs sampled stated the countries of manufacture to be India (n = 148, 34%) and China (n = 71, 16%) (Figure 4). Only five anti-malarial drug brands (87/432, 20% of samples) had obtained WHO prequalification: Coartem (n = 40, Novartis Pharma Ag); Lumart (n = 3, Cipla Ltd); Laritem (n = 3, IPCA Laboratories Ltd); Coarsucam (n = 22, Sanofi Aventis) and Artefan (n = 19, Ajanta Pharma Ltd).
For many brands, the registration status in Gabon is unknown (Table 2).

**Questionnaire**

In total, 209 adults randomly selected from street and market crowds participated in the survey [47]. As a rule of thumb, every fifth passer-by was approached to participate in the survey. Forty-one participants were interviewed at the market in Lambaréné, 98 at the market Mont Bouët in Libreville and 70 at PK8 (transport hub) in Libreville. For 203 people, data were complete; 92% (187/203) of the interviewed people purchased their anti-malarial drugs in a pharmacy, 3.4% in a hospital, 3.4% in a dispensary and 1% (2/203) on the market. Some 51% of the people reported to have a CNAMG (La Caisse Nationale d'Assurance Maladie et de Garantie Sociale du Gabon) health insurance, which means they receive anti-malarial drugs for free in CNAMG affiliated and licensed pharmacies. For detailed results of the questionnaire, see Additional file 6.

**Costs of this study**

The total cost of this study [29] were: €7,578 including the purchase of samples, shipment of samples, transportation costs of the researchers and chemical analysis (GPHF Minilab™ = 4,491, €40, HPLC = in kind contribution), but excluding personnel costs and article-processing charges (Additional file 2).

**Discussion**

This study represents the first systematic and nationwide field survey of anti-malarial drug quality in Gabon. The results are reassuring, as it has been demonstrated that poor-quality anti-malarial drugs were uncommon—only 0.5% of all samples failed the chemical analysis (TLC) and only one sample (AL, Coartem®) could be classified as falsified. The other sample (SP, Maloxine®) was considered as sub-standard as it contained half of the stated dose. The Coartem AL 20/120 mg sample that failed chemical testing was collected in a small pharmacy in Bitam, a town close to the border with Cameroon. This sample is a known fake [44]. In Cameroon, it was found that a large proportion of samples contained either no active ingredient, insufficiently active ingredient, the wrong ingredient, or unknown/unidentifiable ingredient(s) [5]. The authors do not know how this falsified sample ended up for sale in the pharmacy; probably this pharmacy purchased the drugs not via the regular route (the central pharmacy in Libreville), but via drug traders.

Reassuring was that no oral artsunate monotherapy was found. The results of this study are in strong contrast with findings from neighbouring countries [12], where high prevalence of poor-quality anti-malarial drugs have been reported. Using a randomized sampling collection method, fewer poor-quality anti-malarial drugs were identified, compared to previous reports using convenience-sampling methods. A systematic review in 2014 showed that only 5% (six) of 130 published reports included evidence for randomization of sample location selection [12].

The findings of the present study emphasize the need for randomized and reliable sampling methods in order to obtain reliable information on anti-malarial drug quality in a country. It also underpins the notion that there are important caveats to accurately estimate the prevalence and distribution of poor-quality anti-malarials, and that the problem may not be as universally massive as is suggested in the literature [12].

The low proportion of failures could also be explained by the fact that in Gabon, drugs importation and
provision to pharmacies may be subject to better-enforced import regulation compared to other African countries. Theoretically (only, because income is unevenly distributed in Gabon), the average Gabonese resident may be more affluent (Gabon is an upper-middle income country), and thus have easier access and confidence to pharmacies for drug purchase.

A substantial amount of samples (brands) were not WHO-prequalified but registered at national level and refunded by the CNAMGS in Gabon [48, 49]. Registration of anti-malarials with no internationally regulatory clearance at national level may reflect a weakness in the regulatory system of Gabon.

**Strengths and limitations of study**

The sample size in this study is appropriate to make generalizations about the quality of anti-malarial drugs in Gabon. Although the samples analysed in the current study were only collected from pharmacies (and not from markets, street vendors, etc.), the results arguably represent the situation in Gabon. In the experience of the authors and researchers at CERMEL, and as confirmed by the questionnaire results, it is known that most residents purchase their medicines in pharmacies or hospitals. Moreover, 92% of the interviewed people in this study reported to buy their drugs in a pharmacy, although having given 'socially desirable answers' cannot be excluded from this questionnaire. Another limitation of the street questionnaire is that it was conducted in only two cities: Lambaréné and the capital, Libreville. Therefore, these results may differ for other areas of Gabon.

Other strengths of this study are the randomized design and the use of a mystery shopper for the collection of samples [50]. The 11 surveyed cities/towns cover the majority of the relatively small population of Gabon. As can be seen on the map, towns are not evenly distributed across the country; most people live in the west, as the east of Gabon comprises large inaccessible tropical forest areas. All border areas were also covered in this survey: Equatorial Guinea (Libreville and Oyem), Cameroon (Bitam and Oyem), Congo (Francoeurville, Mouila).

The GPHF Minilab® (semi-quantitative layer chromatography) was used to evaluate the quality of anti-malarial drugs. This method does not require specialist training, is simple to use, rapid, robust, reproducible, relatively inexpensive (HPLC of all the samples costs approximately €14,000), and has successfully detected poor-quality drugs before [37, 38, 51–55]. However, it is a screening tool able to give qualitative results as the sensitivity of the method is limited [56]. This means that false negatives might be present. A study conducted by the WHO in six African countries [22] compared the outcomes of quality control laboratory testing and the GPHF-Minilab® screening. It was shown that Minilab screening detected only approximately one in three non-compliant samples. Furthermore, Minilab screening gave some false positive results: 6 of 99 ACT samples (6%) and 1 of 92 SP samples (1%) failed in GPHF-Minilab® screening, but complied with all specifications in quality control laboratory testing. Thus, it can only reliably detect grossly sub-standard samples and therefore should not be used as an independent testing resource or provide quantitative data except in conjunction with a laboratory capable of more sensitive techniques, e.g., HPLC [52].

In this study, the two failed samples were analysed at the reference laboratory based at the London School of Hygiene and Tropical Medicine (LSHTM). Unfortunately, funds were insufficient to analyse all the ‘passed’ samples with HPLC to get a quantitative assessment of samples. However, even if the results underestimate the prevalence with a hypothetical factor 3, the prevalence of poor-quality drugs would be around 1.5%, which is still low (although significant in terms of morbidity and mortality). Thus, the GPHF Minilab® can be useful as a screening tool of anti-malarial drugs through the use of semi-quantitative tests while results of a more thorough and confirmatory laboratory tests are awaited (e.g., mass spectrometry (FI-GRSA-MS) and HPLC) [57].

**Conclusion**

Poor-quality anti-malarials are, according to described findings, uncommon in Gabon. Nevertheless, the Gabonese health authorities should lead an effort to improve regulatory requirements and consolidate regulatory functions, as recommend by WHO. It could also consider publishing and disseminating granted licences for drug manufacturers to improve the regulation of imported drugs.

**Additional files**

Additional file 1: The medicine regulatory system in Gabon. This paragraph describes in brief the medicine regulatory system in Gabon.  
Additional file 2: Study costs. To increase transparency and reproducibility, the costs of this field survey are published. These include for example the laboratory costs, collection of the samples and travel expenses.  
Additional file 3: CERMEL Scientific Review Committee’s study protocol assessment. The assessment of the Scientific Review Committee of the study protocol.  
Additional file 4: Sample collection. The case record form or sample collection form depicts all the information collected during the sampling process.  
Additional file 5: Results of the disintegration test. This document shows the detailed results of the disintegration tests.  
Additional file 6: AMQUAL questionnaire results. This document summarizes the results of the street survey conducted.
Abbreviations
ACT: artemisinin-based combination therapy; ADST: artemisinin derivative screening test; AL: artemether-lumefantrine; AMC: Academic Medical Center; API: active pharmaceutical ingredient; AS + AQ: artesunate + amodiaquine; CERME: Centre de Recherches Médicales de Lambaréné; CNAGMS: La Caisse Nationale d’Assurance Maladie et de Garantie Sociale du Gabon; ERP: expert review panel; FDA: US Food and Drug Administration; GMP: good manufacturing practices; GHF: the global health fund; HPLC: high-performance liquid chromatography; IMPACT: international medical products anti-counterfeiting taskforce; INN: international non-proprietary name; MED-QUARG: Medicine Quality Assessment Reporting Guidelines; MRA: Medicine Regulatory Agency; PH: Eur. European Pharmacopoeia; PQM: promoting the quality of medicines; QC: quality control; SOP: standard operating procedure; SP: sulfadoxine-pyrimethamine; TLC: semi-quantitative thin-layer chromatography; USP: US Pharmacopeia; UV: ultraviolet-visible; WHO: World Health Organization; WWARN: WorldWide Antimalarial Resistance Network.

Authors’ contributions
BJV and MPG conceived the study. BJV, DK and JD collected the samples. BJV performed the statistical analysis and wrote the first draft of the manuscript. BJV and JMG conducted the chemical analysis. RV and BJV conducted the street questionnaire. HK performed the HPLC testing and contributed to writing the manuscript. EB gave practical assistance during the study and monitored the procedures and quality of the study. MPG, MvV, JH, HK, and STA supervised the study and revised the manuscript. All authors read and approved the final manuscript.

Author details
1 Division of Internal Medicine, Department of Infectious Diseases, Center of Tropical Medicine and Travel Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, PO Box 22700, 1100 DE Amsterdam, The Netherlands. 2 Centre de Recherches Médicales de Lambaréné (CERME), Albert Schweitzer Hospital, Lambaréné, Gabon. 3 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany. 4 Department of Pharmaceutical Technology and Biopharmacy, Utrecht University, Utrecht, The Netherlands. 5 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.

Acknowledgements
We would like to thank Roseline Komba and Brigitte Mignonbe of Centre de Recherches Médicales de Lambaréné (CERME) for their supportive field assistance.

Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.

Received: 19 April 2015 Accepted: 3 July 2015 Published online: 15 July 2015

References
1. WHO (2014) Malaria Factsheet No 94. World Health Organization (WHO). http://www.who.int/mediacentre/factsheets/fs094/en/. Accessed 11 Feb 2015
2. Visser BJ, van Vught M, Grobusch MP (2014) Malaria: an update on current chemotherapy. Expert Opin Pharmacother 15:2219–2254
3. Visser BJ, Wieten RW, Kroon D, Nagel IM, Belard S, van Vught M et al (2014) Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J 13:463
4. van Vught M, van Beest A, Sicuri E, van Tulder M, Grobusch MP (2011) Malaria treatment and prophylaxis in endemic and nonendemic countries: evidence on strategies and their cost-effectiveness. Future Microbiol 6:1485–1500
5. Newton PN, Green MD, Mildenhall DC, Plancou A, Nettley H, Nyadong L et al (2011) Poor quality vital anti-malarials in Africa—an urgent neglected public health priority. Malar J 10:352
6. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G et al (2011) The primacy of public health considerations in defining poor quality medicines. PLoS Med 8:e1001139
7. Almuzzaini T, Choona L, Sammons H (2013) Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3:e002923
8. Kelesidis T, Falagas ME (2015) Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev 28:443–464
9. White NJ, Pontavornpipinyo W, Maude RJ, Saralamba S, Agurs R, Stepnowska K et al (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8:253
10. Karunamooorthy K (2014) The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar J 13:209
11. Chaccour C, Kaur H, Del Pozo JL (2015) Falsified antimalarials: a minireview. Expert Rev Anti Infect Ther 13:505–509
12. Tabernero P, Fernandez FM, Green M, Guerin PJ, Newton PN (2014) Mind the gaps—the epidemiology of poor-quality anti-malarials in the malari­ous world—africa of the WorldWide Antimalarial Resistance Network database. Malar J 13:139
13. Tabernero P, Newton PN (2012) The WWARN antimalarial quality surveyor. Pathog Glob Health 106:77–78
14. Assele V, Ndoih N, Nkoghe D, Fandeur T (2015) No evidence of decline in malaria burden from 2006 to 2013 in a rural province of Gabon: implications for public health policy. BMC Public Health 15:81
15. Bouyou-Akotok MK, Offouga CL, Mwili-Mbamba DP, Essou LA, Madoungou B, Komba M (2014) Falciparum malaria as an emerging cause of fever in adults living in Gabon, Central Africa. Biomed Res Int 2014:351281
16. Mawili-Mbamba DP, Bouyou-Akotok MK, Kendoj E, Njabia J, Mediang MO, Mbana JR et al (2013) Increase in malaria prevalence and age of at risk population in different areas of Gabon. Malar J 12:3
17. Savadogo CW, Amodou Al-Kamarany M, Al-Mekhalifi HM, Elkarbame M, Al-Adhnoey AH, Cheriah Y et al (2011) Quality of chloroquine tablets available in Africa. Ann Trop Med Parasitol 105:447–453
18. Basco LK (2004) Molecular epidemiology of malaria in Cameroon. XIX Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 70:245–250
19. Basco LA, Ringwald P, Manene AB, Chanderi J (1997) False chloroquine resistance in Africa. Lancet 350:224
20. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C et al (2006) Manslaughter by fake artesunate in Asia—will Africa be next? PLoS Med 3:e197
21. World Health Organization (WHO) (1995) La qualité des médicaments sur le marché pharmaceutique africain—Étude analytique dans trois pays: Cameroun, Madagascar, Tchad—Série de recherche, No. 18. http://apps.who.int/medicinedocs/en/d/l2212f/. Accessed 11 Feb 2015
22. World Health Organization (WHO) (2013) Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa WHO/QM/12.451. http://www.who.int/medicines/publications/WHO_QM12A5A_report.pdf. Accessed 11 Feb 2015
23. Chaccour CJ, Kaur H, Mabey D, Del Pozo JL (2012) Travel and fake artesunate: a risky business. Lancet 380:1120
24. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S et al (2004) Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9:1241–1246
25. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K et al (2009) Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9:1241–1246
26. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C et al (2006) Manslaughter by fake artesunate in Asia—will Africa be next? PLoS Med 3:e197
27. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C et al (2006) Manslaughter by fake artesunate in Asia—will Africa be next? PLoS Med 3:e197
28. Newton PN, Schellenberg D, Ashley EA, Ravinetto R, Green MD, Kuile FO et al (2015) Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ 350:i2350
29. Visser BJ, Buijink AW, Grobusch MP (2014) Reporting of medical research costs. Improving transparency and reproducibility of medical research. Methods Inf Med 53:329–331
30. National Health & Medical Research Council (NHMRC) (2003) When does quality assurance in health care require independent ethical review? Advice to Institutions, Human Research Ethics Committees and Health Care Professionals. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ue16.pdf. Accessed 03 Feb 2015

31. WHO (2014) World malaria report. Country profile Gabon p 103. http://www.who.int/malaria/publications/country-profiles/province_bag_en.pdf?ua=1. Accessed 10 Feb 2015

32. (2013) Conférence Internationale des Ordres de Pharmaciens Franco‑phones. Gabon. http://www.ciofpf.org/Fiches‑des‑pays/Gabon. Accessed 11 Feb 2015

33. Liste des Centres Agrees. La Caisse nationale d’assurance maladie et de garantie sociale du Gabon. http://www.cnagms.com/les‑etablissements‑agrees‑par‑la‑cnagms/les‑pharmacies‑agrees‑par‑la‑cnagms/. Accessed 04 Feb 2015

34. Sullivan KM (2015) Open source epidemiologic statistics for public health. Sample size. OpenEpi. http://www.openepi.com/SampleSize/SSPropor.htm. Accessed 04 Feb 2015

35. Phanouvong S, Blum N, Smine A (2004) Guidelines for sampling of antimalarial drug samples in the USP DQI antimalarial drug quality monitoring project in Mekong sub‑region countries. USP http://www.usp.org/sites/default/files/usp_pdf/EN/dqi/dqiamatelscontrolprocedures.pdf. Accessed 04 Feb 2015

36. Global Pharma Health Fund E.V. (2013) Methods for implementing a medicine outlet survey: lessons from the anti‑malarial market. Malar J 12:52

37. Bate R, Hess K (2010) Anti‑malarial drug quality in Lagos and Accra—a pilot study of essential drug quality in two major cities in India. PLoS One 4:e6003

38. Isot J, Kaur H (2009) Simple field assays to check quality of current artemisinin‑based antimalarial combination formulations. PLoS One 4:e7270

39. (2015) European Pharmacopoeia (Ph. Eur.) 8th edition. European Directorate for the Quality of Medicines & Health Care. Desintegration. https://www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html. Accessed 10 Feb 2015

40. WHO (2014) Guidelines on the implementation of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce. World Health Organization, Geneva. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/certification/guidelines/en/index6.html. Accessed 11 Feb 2015

41. Kaur H, Allan EL, Mamadu I, Hall Z, Ibe O, El Sherbiny M et al (2015) Quality of artemisinin‑based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in enugu, Nigeria. PLoS One 10:e0125577

42. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363

43. Verbeke M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C et al (2011) Stability‑indicating HPLC‑DAD/UV‑ESI/MS impurity profiling of the anti‑malarial drug lumefantrine. Malar J 10:51

44. World Health Organization (WHO) (2013) False‑positive duplicates of Coartem recently circulating in Western and Central Africa. http://www.who.int/entity/medicines/publications/drugalerts/Alert_127_Info_Coartem.doc. Accessed 11 Feb 2015

45. Faucon B, Murphy C, Whalen J (2013) Africa’s malaria battle: fake drug pipeline undercuts progress. Wall Street J. http://www.wsj.com/articles/SB10001424127887324474004578449492847128204. Accessed 11 Feb 2015

46. Newton PN, Tabernero P, Dwivedi P, Cuzon MJ, Monge ME, Swaminoss et al (2014) Falsified medicines in Africa: all talk, no action. Lancet Glob Health. 2:e509–e510

47. Miller KW, Wilder LB, Stillman FA, Becker DM (1997) The feasibility of a street‑intercept survey method in an African‑American community. Am J Public Health 87:655–658

48. Agnandji ST, Kurth F, Belard S, Mombo‑Ngoma G, Basra A, Fernandes JF et al (2011) Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub‑Saharan Africa. Wien Klin Wochenschr. 123(Suppl 1):7–9

49. Agnandji ST, Kurth F, Fernandes JF, Soulouma S, Abossolo BP, Mombo‑Ngoma G et al (2011) The use of paediatric artemisinin combinations in sub‑Saharan Africa: a snapshot questionnaire survey of health care personnel. Malar J 10:365

50. O’Connell KA, Poyer S, Solomon T, Munroe E, Patoiuilard E, Njogu J et al (2013) Methods for implementing a medicine outlet survey: lessons from the anti‑malarial market. Malar J 12:52

51. Tipeke M, Diallo S, Coulibaly B, Storzinger D, Hoppe‑Tichy T, Sie A et al (2008) Substandard anti‑malarial drugs in Burkina Faso. Malar J 7:95

52. Risha PG, Misua Z, Clark M, Johnson K, Ndonom‑Srigonda M, Layloff T (2008) The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. Health Policy 87:217–222

53. Odaiga J, Sinclair D, Lokong JA, Donegan S, Hopkins H, Garner P (2014) Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings. Cochrane Database Syst Rev 4:CD008898

54. Phanouvong S, Djaiba Y, Vijayakagda S, Raymond C, Krech L, Lukulay P et al (2013) The quality of antimalarial medicines in eastern Thailand: a case study along the Thai‑Cambodian border. Southeast Asian J Trop Med Public Health 44:363–373

55. Phanouvong S, Raymond C, Krech L, Djaiba Y, Mam B, Lukulay P et al (2013) The quality of antimalarial medicines in western Cambodia: a case study along the Thai‑Cambodian border. Southeast Asian J Trop Med Public Health 44:349–362

56. Bate R, Hess K (2010) Anti‑malarial drug quality in Lagos and Accra—a comparison of various quality assessments. Malar J 9:157

57. Hoellein L, Holzgrabe U (2014) Development of simplified HPLC methods for the detection of counterfeit antimalarials in resource‑restraint environments. J Pharm Biomed Anal 98:434–445